Publication

Article

Evidence-Based Oncology

February 2018
Volume24
Issue 2

eAppendix

Author(s):

Dave Nellesen, PhD,Katerine Dea, MSc

References for: Reimbursement Landscape for Molecular Testing in Non-Small Cell Lung Cancer

Download PDF: eAppendix

Articles in this issue
Medical World News: Clinical/Managed Care Updates
Medical World News: Clinical Updates
Medical World News: Regulatory Updates
Future Shock: Embracing Disruption in the Immunotherapy Revolution
With Approval of CAR T-Cell Therapy Comes the Next Challenge: Payer Coverage
Provocative Questions, Better Biomarkers, and the Prospect of Triple Therapy: A Conversation With NYU's Jeffrey S. Weber, MD, PhD

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Subscribe Now!
Related Videos
Clayton Irvine, PharmD, MBA, MS
Related Content
AJMC
August 15th 2025

Trends in Glucagon-Like Peptide 1 Receptor Agonist Prescribing Patterns

Maria Ukhanova, MD, PhD Joseph S. Wozny, MPH Chau N. Truong, PhD Lopita Ghosh, MBA Trudy M. Krause, DrPH
Managed Care Cast
August 15th 2025

Navigating Risk, Treatment, and Reimbursement in Precision Oncology: Sadie Dobrozsi, MD

Giuliana Grossi Sadie Dobrozsi, MD, MS Interview by Mary Caffrey
AJMC
August 15th 2025

Temporal Shift in Prevalence of Heart Failure Diagnoses and Comorbidities Within 2 US Integrated Health Systems

Mario Enrico Canonico, MD, PhD Judith Hsia, MD Shih-Ting Chiu, PhD Pu-Kai Tseng James O. Mudd, MD Joshua D. Remick, MD Bansi Patel, MS Ya-Hsiu Chuang, PhD Ty J. Gluckman, MD, MHA, FACC, FAHA, FASPC Marc P. Bonaca, MD, MPH
managed care cast logo
August 15th 2025

Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions

Brooke McCormick
AJMC
August 15th 2025

Care Quality Metrics in Medicare During COVID-19 Pandemic

Jeanette Thornton, MPA Mark Hamelburg, JD Lynn Nonnemaker, PhD Sherzod Abdukadirov, PhD German Veselovskiy, MPP Sari Siegel, PhD
Dordaviprone is indicated for recurrent H3 K27M-mutant diffuse midline glioma, an ultra-rare, aggressive brain tumor primarily affecting children. | Image credit: wladimir1804 - stock.adobe.com
August 15th 2025

FDA Approves Dordaviprone as First and Only Treatment for Aggressive Form of Glioma

Rose McNulty

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo